ES2670668T3 - Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica - Google Patents

Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica Download PDF

Info

Publication number
ES2670668T3
ES2670668T3 ES13798222.9T ES13798222T ES2670668T3 ES 2670668 T3 ES2670668 T3 ES 2670668T3 ES 13798222 T ES13798222 T ES 13798222T ES 2670668 T3 ES2670668 T3 ES 2670668T3
Authority
ES
Spain
Prior art keywords
masp
treatment
paroxysmal nocturnal
nocturnal hemoglobinuria
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13798222.9T
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Gregory A. Demopulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Application granted granted Critical
Publication of ES2670668T3 publication Critical patent/ES2670668T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

Una composición que comprende una cantidad de un agente inhibidor de la MASP-3, eficaz para inhibir la activación del complemento dependiente de la MASP-3, para usar en el tratamiento de un sujeto que padece de hemoglobinuria paroxística nocturna (HPN), en la que dicho agente inhibidor de la MASP-3 es un anticuerpo monoclonal de la MASP-3 o un fragmento del mismo que se une específicamente a una porción de la MASP-3humana (ID. DE SEC. N.º 8).
ES13798222.9T 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica Active ES2670668T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
US201261621461P 2012-04-06
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
ES2670668T3 true ES2670668T3 (es) 2018-05-31

Family

ID=49325295

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13798222.9T Active ES2670668T3 (es) 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica
ES18158799T Active ES2894944T3 (es) 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-2 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18158799T Active ES2894944T3 (es) 2012-04-06 2013-04-05 Composiciones y métodos para inhibir la MASP-1 y/o la MASP-2 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica

Country Status (29)

Country Link
US (3) US20130273053A1 (es)
EP (2) EP2833907B1 (es)
JP (3) JP6366571B2 (es)
KR (2) KR102142508B1 (es)
CN (1) CN104661676A (es)
AU (3) AU2013267909B2 (es)
BR (1) BR112014024793A2 (es)
CA (2) CA3087933A1 (es)
CL (1) CL2014002694A1 (es)
CY (1) CY1120736T1 (es)
DK (2) DK2833907T3 (es)
ES (2) ES2670668T3 (es)
HK (1) HK1206996A1 (es)
HR (1) HRP20180671T1 (es)
HU (1) HUE036930T2 (es)
IL (2) IL234991B (es)
IN (1) IN2014KN02324A (es)
LT (1) LT2833907T (es)
MX (2) MX2018008658A (es)
NO (1) NO2881536T3 (es)
NZ (2) NZ781091A (es)
PL (2) PL2833907T3 (es)
PT (1) PT2833907T (es)
RS (1) RS57266B1 (es)
RU (2) RU2018114903A (es)
SI (1) SI2833907T1 (es)
TR (1) TR201806939T4 (es)
WO (1) WO2013180834A2 (es)
ZA (1) ZA201408100B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102024016B1 (ko) * 2011-05-04 2019-11-04 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
KR20220100997A (ko) * 2012-06-18 2022-07-18 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
EP2968546B1 (en) * 2013-03-15 2023-09-20 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN110177875B (zh) 2016-11-28 2023-11-28 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
EP3606965A4 (en) 2017-04-03 2021-01-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MASP-1 ANTIBODIES AND METHODS OF USE
CA3099753A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
CN114302719A (zh) * 2019-07-31 2022-04-08 拜奥克里斯特制药公司 口服补体因子d抑制剂的给药方案
CA3159172A1 (en) 2019-12-04 2021-06-10 Michael Cicirelli Masp-2 inhibitors and methods of use
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP1238066A2 (en) * 1999-12-02 2002-09-11 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
CN101897969B (zh) * 2003-02-21 2014-04-02 健泰科生物技术公司 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
WO2005075665A2 (en) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602006004582D1 (de) * 2006-07-31 2009-02-12 Fiat Ricerche Durch eine Fluidströmung betätigbarer elektrischer Generator
ES2628973T3 (es) 2007-05-31 2017-08-04 University Of Washington Mutagénesis inducible de genes diana
KR20110047255A (ko) * 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20120022543A1 (en) * 2009-03-05 2012-01-26 Smith & Nephew, Inc. System, method, and apparatus for locating a femoral neck guide wire
EP3395828A1 (en) * 2009-07-17 2018-10-31 Rigshospitalet Inhibitors of complement activation
CN102958535A (zh) * 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
EP2694108B1 (en) * 2011-04-08 2018-06-06 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation

Also Published As

Publication number Publication date
KR102142508B1 (ko) 2020-08-10
HUE036930T2 (hu) 2018-08-28
CA3087933A1 (en) 2013-12-05
IL234991A0 (en) 2014-12-31
HK1206996A1 (en) 2016-01-22
JP2015514117A (ja) 2015-05-18
IL274721B (en) 2022-04-01
EP2833907B1 (en) 2018-02-28
WO2013180834A3 (en) 2014-04-03
NO2881536T3 (es) 2018-06-30
BR112014024793A2 (pt) 2019-08-27
US20190382505A1 (en) 2019-12-19
AU2020204163A1 (en) 2020-07-09
JP2018162307A (ja) 2018-10-18
AU2013267909A1 (en) 2014-11-27
CY1120736T1 (el) 2019-12-11
NZ781091A (en) 2022-04-29
CA2869326A1 (en) 2013-12-05
AU2018200721B2 (en) 2020-03-26
EP3366307B1 (en) 2021-07-28
JP6815355B2 (ja) 2021-01-20
EP3366307A1 (en) 2018-08-29
RU2655299C2 (ru) 2018-05-24
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
IN2014KN02324A (es) 2015-05-01
MX357540B (es) 2018-07-13
US20220242972A1 (en) 2022-08-04
JP2021001199A (ja) 2021-01-07
KR20200097808A (ko) 2020-08-19
IL274721A (en) 2020-07-30
IL234991B (en) 2020-06-30
CL2014002694A1 (es) 2015-08-28
EP2833907A4 (en) 2016-03-16
ZA201408100B (en) 2022-05-25
US20130273053A1 (en) 2013-10-17
KR20150003785A (ko) 2015-01-09
DK2833907T3 (en) 2018-05-28
RU2018114903A3 (es) 2021-08-12
AU2013267909B2 (en) 2018-03-01
PL2833907T3 (pl) 2018-08-31
ES2894944T3 (es) 2022-02-16
RU2018114903A (ru) 2019-03-04
SI2833907T1 (en) 2018-07-31
RU2014144621A (ru) 2016-05-27
WO2013180834A2 (en) 2013-12-05
JP6366571B2 (ja) 2018-08-01
PT2833907T (pt) 2018-05-29
EP2833907A2 (en) 2015-02-11
CN104661676A (zh) 2015-05-27
RS57266B1 (sr) 2018-08-31
AU2018200721A1 (en) 2018-02-22
PL3366307T3 (pl) 2022-03-07
LT2833907T (lt) 2018-06-11
NZ629675A (en) 2017-02-24
KR102318623B1 (ko) 2021-11-02
HRP20180671T1 (hr) 2018-07-13
NZ727063A (en) 2021-10-29
MX2018008658A (es) 2021-10-19
CA2869326C (en) 2021-09-21
DK3366307T3 (da) 2021-11-01

Similar Documents

Publication Publication Date Title
ES2670668T3 (es) Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
ES2683307T3 (es) Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
MY195432A (en) Methods For Inhibiting Angiogenesis In A Subject In Need Thereof
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
BR112013029330A2 (pt) "uso de anticorpo imunoconjugado maitansinoide anti-cd19 na preparação de composição para tratamento de sintomas de doenças de célula-b, imunoconjugado maitansinoide anti-cd19 e artigo de fabricação"
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
AR101740A1 (es) Terapia de combinación y composiciones
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
EA201990298A1 (ru) Способы и композиции для лечения рака
EA201400748A1 (ru) Композиция для обработки семян
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.